(i) a third party interested in an individual gene target would provide a bona fide development plan,
#WHAT SEED TO USE TO GENERATE LICENSE LICENSE#
However, after an initial period, other companies may apply to license certain CRISPR IP for use against genes that are not being pursued by the primary licensee. Broad Institute, Harvard, and MIT therefore developed an approach that we call an “inclusive innovation” model. Under this model, Broad, Harvard, and MIT license CRISPR technology to a primary licensee.For human therapeutics, we concluded that exclusivity is necessary to drive the level of investment needed to develop certain technologies to the point that they are safe, effective, and capable of precise editing in specific cell types.For companies wishing to sell tools and reagents for genome editing, we also license CRISPR IP non-exclusively.For research by companies, we license CRISPR IP non-exclusively.Further, non-profit institutions and government agencies may transfer materials they generate in the conduct of such internal research to other non-profit institutions or government agencies under the terms of the UBMTA (Uniform Biological Material Transfer Agreement) without needing to receive a further written license from Broad. Non-profit institutions and government agencies do not need to receive a written license from Broad to conduct internal research, including sponsored research to the extent such research does not include the production or manufacture of products for sale or offer for sale or performance of commercial services for a fee. For these communities we make CRISPR tools, knowledge, methods and other IP for genome-editing freely available for research. Since February 2013, Addgene has shared more than 57,500 plasmids and reagents from the Zhang Lab with more than 2,830 institutions across 71 countries to help accelerate research into virtually every aspect of human health - including cancer, schizophrenia, diabetes, HIV and other infectious diseases. For academic and non-profit research use, no written license is necessary.(In particular, any human clinical use must be consistent with all laws and regulations, and we do not license the technology for clinical use of human germline editing.) We also consider important ethical,safety and societal concerns. We are committed to making these technologies broadly available for research to help ensure that therapeutic development - bringing this technology to the clinic - has the best chance of success. Next Generation in Biomedicine Symposiumīroad Institute, MIT and Harvard share the goal of developing innovative technologies such as CRISPR genome editing tools and promoting its translation into therapies to benefit patients.Science Writing and Communications Internship.Stanley Center for Psychiatric Research.
0 kommentar(er)
